证券日报网讯 10月23日晚间，热景生物发布公告称，公司于2025年10月23日召开第四届董事会第五次 会议审议通过《关于参股公司增资扩股实施股权激励暨关联交易的议案》。公司参股公司北京舜景生物 医药技术有限公司（简称"舜景医药"）拟通过新设立有限合伙企业（员工持股平台）对舜景医药进行增 资并实施股权激励，拟增资总金额为4，000万元，认购400万新增注册资本，差额部分计入资本公积。 公司拟放弃本次增资的优先认购权。公司控股股东、实际控制人、董事长、总经理林长青担任舜景医药 董事长。舜景医药拟设立的员工持股平台拟由林长青担任普通合伙人。公司作为舜景医药的股东，放弃 对舜景医药本次增资的优先认购权，构成关联交易。本次关联交易尚需提交股东会审议。 （文章来源：证券日报） ...

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]

Group 1 - HuanGong Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [1] - XinLai YingCai's subsidiary plans to invest 2 billion yuan in a semiconductor core component project, aiming for an annual output value exceeding 1.5 billion yuan [2] - ChuanFa LongMang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project to strengthen its new energy materials business [4] Group 2 - YouFa Group reported a net profit increase of 2320.53% in Q3, with a revenue of 13.104 billion yuan, down 3.97% year-on-year [6] - ZhuoYi Information's Q3 net profit rose by 2074.65%, with revenues of 88.8168 million yuan, up 2.52% year-on-year [5] - BeiFang Navigation's Q3 net profit increased by 1681.27%, with revenues of 765 million yuan, up 52.12% year-on-year [6] Group 3 - TianNeng Heavy Industry reported a Q3 net profit growth of 1359.03%, with revenues of 1.055 billion yuan, up 59.33% year-on-year [7][8] - TeYi Pharmaceutical's Q3 net profit increased by 985.18%, with revenues of 201 million yuan, up 41.49% year-on-year [9] - HuaLv Biological's Q3 net profit grew by 619.37%, with revenues of 369 million yuan, up 35.24% year-on-year [10] Group 4 - ShengYi Electronics expects a net profit increase of 476% to 519% for the first three quarters, with revenues projected between 6.614 billion yuan and 7.034 billion yuan [12] - YingLi Co., Ltd. reported a Q3 net profit increase of 229.14%, with revenues of 581 million yuan, up 14.73% year-on-year [13] - GuangKang Biochemical's Q3 net profit increased by 236.87%, with revenues of 151 million yuan, down 9.41% year-on-year [14] Group 5 - High-speed Electric reported a Q3 net profit growth of 242.35%, with revenues of 277 million yuan, up 44.51% year-on-year [15] - Wide Special Materials reported a Q3 net profit increase of 213.65%, with revenues of 1.24 billion yuan, up 15.03% year-on-year [16] - BaoFeng Energy's Q3 net profit increased by 162.34%, with revenues of 12.725 billion yuan, up 72.49% year-on-year [17] Group 6 - Sanfu Co., Ltd. reported a Q3 net profit increase of 162.25%, with revenues of 540 million yuan, up 23.52% year-on-year [18] - WuKang New Energy's Q3 net profit increased by 106.31%, with revenues of 2.15 billion yuan, up 69.79% year-on-year [19] - PaiNeng Technology's Q3 net profit grew by 94.01%, with revenues of 863 million yuan, up 56.13% year-on-year [20] Group 7 - SanSheng GuoJian reported a Q3 net profit increase of 71.15%, with revenues of 474 million yuan, up 38.27% year-on-year [21] - ReJing Biological reported a net loss of 109 million yuan for the first three quarters, with revenues of 310 million yuan, down 19.8% year-on-year [22] - JiangShan OuPai reported a Q3 net loss of 51.58 million yuan, with revenues of 416 million yuan, down 48.92% year-on-year [23][24]

智通财经APP讯，热景生物(688068.SH)披露2025年第三季度报告，公司前三季度实现营收3.1亿元，同 比下降19.8%;归属于上市公司股东的净利润亏损1.09亿元;扣非净利润亏损1.48亿元;基本每股收益-1.23 元。 ...

Core Viewpoint - The company reported a significant decline in revenue and incurred a net loss in the third quarter of 2023, indicating potential challenges in its financial performance moving forward [1]. Financial Performance - For the first three quarters of 2023, the company's revenue was approximately 310 million yuan, representing a year-on-year decrease of 19.8% [1]. - The net profit attributable to shareholders of the listed company was a loss of approximately 109 million yuan [1]. Market Position - As of the report date, the company's market capitalization stood at 15.3 billion yuan [2].

北京热景生物技术股份有限公司（以下简称"公司"或"热景生物"）于 2025 年 10 月 23 日召开了第四届董事会第五次会议，审议通过了《关于调整独 立董事薪酬的议案》。现将具体情况公告如下： 证券代码：688068 证券简称：热景生物 公告编号：2025-069 北京热景生物技术股份有限公司 关于调整独立董事薪酬的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 24 日 1 根据《上市公司独立董事管理办法》等有关法律法规及《公司章程》的规定， 综合考虑独立董事为公司的规范运作、治理体系建设和可持续发展等方面做出的 重要贡献，并结合公司发展情况及独立董事的专业度和敬业度，公司拟将独立董 事薪酬由每人每年度税前 15 万元人民币调整为每人每年度税前 18 万元人民币。 本次独立董事薪酬调整事项，旨在进一步强化独立董事的勤勉尽责意识，有 利于公司独立董事更好地参与公司治理工作，符合公司长远发展需要，不存在损 害公司利益及全体股东特别是中小股东利益的情形。 鉴于该事项与公司所有独立董事均存在关联关 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-068 北京热景生物技术股份有限公司 关于增加公司 2025 年度日常关联交易预计额度 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：是 日常关联交易对上市公司的影响：公司与关联方所发生的日常关联交易 属于公司从事生产经营活动的正常业务往来，符合正常商业逻辑及公平原则，在 双方平等协商达成的交易协议的基础上实施，交易条件及定价公允，并按照相关 规定履行批准程序，不存在损害公司和股东利益的情形。进行上述相关日常关联 交易对公司主营业务不构成重大影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 10 月 23 日召开了第四届董事会第五次会议，审议通过了《关 于增加公司 2025 年度日常关联交易预计额度的议案》，公司董事会在审议该议 案时，关联董事林长青先生回避表决，出席会议的非关联董事一致同意该议案。 此议案审议程序符合相关法律法规的规定。 公司于 2025 年 10 月 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-070 2025年第四次临时股东会 召开日期时间：2025 年 11 月 10 日 14 点 30 分 召开地点：北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路 55 号公司三层会议室 （五） 网络投票的系统、起止日期和投票时间。 北京热景生物技术股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 10 日 至2025 年 11 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2025年11月10日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期 ...

北京热景生物技术股份有限公司 2025 年第三季度报告 证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告 中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 14 单位：元 币种：人民币 项目 本报告期 本报告 期比上 年同期 增减变 动幅度 (%) 年初至报告期末 年初至报 告期末比 上年同期 增减变动 幅度(%) 营业收入 105,795,807.88 -22.98 309,709,122.21 -19.80 利润总额 -20,917,096.86 -500.63 -112,139,044.10 196.26 归属于上市公 ...

交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热 景生物"）参股公司北京舜景生物医药技术有限公司（以下简称"舜景医药"） 拟通过新设立有限合伙企业（员工持股平台）对舜景医药进行增资并实施股权激 励，拟增资总金额为 4,000 万元，认购 400 万新增注册资本，差额部分计入资本 公积。公司拟放弃本次增资的优先认购权。 证券代码：688068 证券简称：热景生物 公告编号：2025-067 北京热景生物技术股份有限公司 关于参股公司增资扩股实施股权激励暨关联交易 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司控股股东、实际控制人、董事长、总经理林长青担任舜景医药董事 长。舜景医药拟设立的员工持股平台拟由林长青担任普通合伙人。公司作为舜景 医药的股东，放弃对舜景医药本次增资的优先认购权，构成关联交易，但不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。至本次关联交易为止， 过去 12 个月内上市公司与同一关联人之间进行的交易达到 3,000 万元以上，且 占上市公司最近一期 ...